CN114437052B - 一种利用连续流微通道反应器合成他汀类药物中间体的方法 - Google Patents
一种利用连续流微通道反应器合成他汀类药物中间体的方法 Download PDFInfo
- Publication number
- CN114437052B CN114437052B CN202111664851.2A CN202111664851A CN114437052B CN 114437052 B CN114437052 B CN 114437052B CN 202111664851 A CN202111664851 A CN 202111664851A CN 114437052 B CN114437052 B CN 114437052B
- Authority
- CN
- China
- Prior art keywords
- solution
- synthesizing
- reaction
- continuous flow
- micro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 20
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 42
- 230000035484 reaction time Effects 0.000 claims abstract description 20
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims abstract description 15
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000005086 pumping Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 27
- 239000000543 intermediate Substances 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 239000003054 catalyst Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000010924 continuous production Methods 0.000 abstract 1
- 239000010815 organic waste Substances 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- QGAVSDVURUSLQK-UHFFFAOYSA-N ammonium heptamolybdate Chemical compound N.N.N.N.N.N.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Mo].[Mo].[Mo].[Mo].[Mo].[Mo].[Mo] QGAVSDVURUSLQK-UHFFFAOYSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0093—Microreactors, e.g. miniaturised or microfabricated reactors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111664851.2A CN114437052B (zh) | 2021-12-31 | 2021-12-31 | 一种利用连续流微通道反应器合成他汀类药物中间体的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111664851.2A CN114437052B (zh) | 2021-12-31 | 2021-12-31 | 一种利用连续流微通道反应器合成他汀类药物中间体的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114437052A CN114437052A (zh) | 2022-05-06 |
CN114437052B true CN114437052B (zh) | 2024-03-29 |
Family
ID=81365132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111664851.2A Active CN114437052B (zh) | 2021-12-31 | 2021-12-31 | 一种利用连续流微通道反应器合成他汀类药物中间体的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114437052B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1436174A (zh) * | 2000-06-15 | 2003-08-13 | 布里斯托尔-迈尔斯斯奎布公司 | HMG-CoA还原酶抑制剂及其作为治疗与胆固醇相关疾病的药物的应用 |
CN1436192A (zh) * | 2000-06-15 | 2003-08-13 | 布里斯托尔-迈尔斯斯奎布公司 | HMG-CoA还原酶抑制剂及方法 |
KR20120001306A (ko) * | 2010-06-29 | 2012-01-04 | 주식회사종근당 | 티오에스터 화합물, 술폰 화합물 및 이를 이용한 피타바스타틴 또는 이의 약제학적으로 허용 가능한 염의 제조방법 |
CN103328470A (zh) * | 2011-01-18 | 2013-09-25 | 中化帝斯曼制药有限公司荷兰公司 | 制备二醇砜的方法 |
CN103649068A (zh) * | 2011-07-19 | 2014-03-19 | 广东东阳光药业有限公司 | 一种他汀类药物中间体和其制备方法 |
CN104058911A (zh) * | 2014-07-10 | 2014-09-24 | 联化科技股份有限公司 | 一种利用微通道反应器制备亚砜或砜的方法 |
CN111100046A (zh) * | 2018-10-29 | 2020-05-05 | 中国石油化工股份有限公司 | 一种硫醚氧化方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ304171B6 (cs) * | 2011-12-16 | 2013-12-04 | Zentiva, K.S. | Zpusob prípravy chránených chirálních sulfon - diolu |
-
2021
- 2021-12-31 CN CN202111664851.2A patent/CN114437052B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1436174A (zh) * | 2000-06-15 | 2003-08-13 | 布里斯托尔-迈尔斯斯奎布公司 | HMG-CoA还原酶抑制剂及其作为治疗与胆固醇相关疾病的药物的应用 |
CN1436192A (zh) * | 2000-06-15 | 2003-08-13 | 布里斯托尔-迈尔斯斯奎布公司 | HMG-CoA还原酶抑制剂及方法 |
KR20120001306A (ko) * | 2010-06-29 | 2012-01-04 | 주식회사종근당 | 티오에스터 화합물, 술폰 화합물 및 이를 이용한 피타바스타틴 또는 이의 약제학적으로 허용 가능한 염의 제조방법 |
CN103328470A (zh) * | 2011-01-18 | 2013-09-25 | 中化帝斯曼制药有限公司荷兰公司 | 制备二醇砜的方法 |
CN103649068A (zh) * | 2011-07-19 | 2014-03-19 | 广东东阳光药业有限公司 | 一种他汀类药物中间体和其制备方法 |
CN104058911A (zh) * | 2014-07-10 | 2014-09-24 | 联化科技股份有限公司 | 一种利用微通道反应器制备亚砜或砜的方法 |
CN111100046A (zh) * | 2018-10-29 | 2020-05-05 | 中国石油化工股份有限公司 | 一种硫醚氧化方法 |
Non-Patent Citations (1)
Title |
---|
Chemoenzymatic synthesis of statine side chain building blocks and application in the total synthesis of the cholesterol-lowering compound solistatin;Oliver Rieder,等;Journal of Biotechnology;171-180 * |
Also Published As
Publication number | Publication date |
---|---|
CN114437052A (zh) | 2022-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109776462A (zh) | 一种2,5-二氰呋喃的制备方法 | |
BR102018002949B1 (pt) | método de preparação de intermediários de azoxistrobina | |
CN103922965B (zh) | 一种4-甲氧基-2-甲基苯乙腈的合成方法 | |
CN110734394B (zh) | 一种3,6-二氢吡啶酮化合物的合成方法 | |
CN114437052B (zh) | 一种利用连续流微通道反应器合成他汀类药物中间体的方法 | |
CN104592104B (zh) | 一种制备2‑氯烟酸的方法 | |
CN105440012A (zh) | 一种来那度胺及其中间体的制备方法 | |
CN103896858A (zh) | 胞嘧啶的制备工艺 | |
CN102286036A (zh) | 红景天苷的合成方法 | |
CN114315609B (zh) | 一种制备顺式2-氨基环己醇的工艺方法 | |
CN114989061A (zh) | 一种布瓦西坦的制备方法 | |
EP3896057B1 (en) | Method for continuously preparing citalopram diol | |
CN110615752B (zh) | 一种离子液体催化贝克曼重排制备己内酰胺的方法 | |
CN109096226B (zh) | 以2,1,3-苯并噻二唑为导向基的芳基碳氢活化乙酰氧基化方法 | |
CN109503545B (zh) | 一种1,4-环己二酮单乙二醇缩酮的制备方法 | |
CN114163364A (zh) | 2-甲氧基烯丙基磺酸酯及其合成方法 | |
CN103787921B (zh) | 一种制备高光学纯度的反式1,2-环二胺的方法 | |
CN101735241A (zh) | 普拉格雷中间体及其制备方法 | |
CN113801079B (zh) | 一种呋虫胺代谢物uf的合成方法 | |
CN104591939B (zh) | 一种制备联苯基丙烯酸醚类化合物的方法 | |
CN110283129A (zh) | 一种合成全碳基取代嘧啶衍生物的方法 | |
CN115215767B (zh) | 制备2-氰基-3-乙氧基丙烯酸乙酯衍生物的方法 | |
CN113773250B (zh) | 一种5-氰基-8-酰氨基喹啉类化合物及其制备方法 | |
CN103980328A (zh) | 一种2-脱氧-d-葡萄糖的制备方法 | |
CN103421855B (zh) | 一种制备琥珀酸夫罗曲坦关键中间体的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Country or region after: China Address after: No. 8, Zhongxing Road, Ecological Chemical Technology Industrial Park, Suqian City, Jiangsu Province, 223800 Applicant after: Jiangsu Alpha Group Furui Pharmaceutical (Suqian) Co.,Ltd. Address before: 211313 No. 8, Zhongxing Road, ecological Chemical Technology Industrial Park, Suqian City, Jiangsu Province Applicant before: Jiangsu Furui Kangtai Pharmaceutical Co.,Ltd. Country or region before: China |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for synthesizing statin drug intermediates using a continuous flow microchannel reactor Granted publication date: 20240329 Pledgee: Industrial Bank Co.,Ltd. Suqian Branch Pledgor: Jiangsu Alpha Group Furui Pharmaceutical (Suqian) Co.,Ltd. Registration number: Y2024980013386 |